Eupraxia Pharmaceuticals Inc.
EPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $275 | $207 | $117 | $113 |
| - Cash | $124 | $20 | $27 | $33 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $151 | $187 | $90 | $80 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$9 | -$12 | -$10 | -$11 |
| % Margin | – | – | – | – |
| Net Income | -$9 | -$12 | -$10 | -$11 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.26 | -0.33 | -0.3 | -0.21 |
| % Growth | 21.2% | -10% | -42.9% | – |
| Operating Cash Flow | -$5 | -$8 | -$6 | -$6 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$5 | -$8 | -$6 | -$6 |